Methods for screening compounds for proarrhythmic risk and antiarrhythmic efficacy
    1.
    发明授权
    Methods for screening compounds for proarrhythmic risk and antiarrhythmic efficacy 失效
    筛选化合物用于心律失常风险和抗心律失常药效的方法

    公开(公告)号:US07396524B2

    公开(公告)日:2008-07-08

    申请号:US11194983

    申请日:2005-08-02

    Applicant: Gan-Xin Yan

    Inventor: Gan-Xin Yan

    CPC classification number: G01N33/5088 G01N33/6872 G01N2500/04 G01N2800/326

    Abstract: Methods for screening compounds for their potential to induce or inhibit a cardiac arrhythmia are disclosed. The methods comprise determining the ratio of the time constant (τ) of ICa,L recovery in tissue expressing the L-type calcium channel or any subunit or combination thereof of the L-type calcium channel treated with a test compound to the ventricular repolarization time of cardiac tissue treated with a test compound. The methods further comprise determining an arrhythmic risk score for a specified dose of a test compound.

    Abstract translation: 公开了筛选化合物诱导或抑制心律不齐的潜力的方法。 所述方法包括确定表达L型钙通道的组织中的ITA,L +回收的时间常数(τ)与其治疗的L型钙通道的任何亚基或其组合的比率 使用测试化合物治疗的心脏组织的心室复极化时间的测试化合物。 所述方法还包括确定特定剂量的测试化合物的心律失常风险评分。

    Methods for screening compounds for proarrhythmic risk and antiarrhythmic efficacy
    2.
    发明申请
    Methods for screening compounds for proarrhythmic risk and antiarrhythmic efficacy 失效
    筛选化合物用于心律失常风险和抗心律失常药效的方法

    公开(公告)号:US20070031817A1

    公开(公告)日:2007-02-08

    申请号:US11194983

    申请日:2005-08-02

    Applicant: Gan-Xin Yan

    Inventor: Gan-Xin Yan

    CPC classification number: G01N33/5088 G01N33/6872 G01N2500/04 G01N2800/326

    Abstract: Methods for screening compounds for their potential to induce or inhibit a cardiac arrhythmia are disclosed. The methods comprise determining the ratio of the time constant (τ) of ICa,L recovery in tissue expressing the L-type calcium channel or any subunit or combination thereof of the L-type calcium channel treated with a test compound to the ventricular repolarization time of cardiac tissue treated with a test compound. The methods further comprise determining an arrhythmic risk score for a specified dose of a test compound.

    Abstract translation: 公开了筛选化合物诱导或抑制心律不齐的潜力的方法。 所述方法包括确定表达L型钙通道的组织中的ITA,L +回收的时间常数(τ)与其治疗的L型钙通道的任何亚基或其组合的比率 使用测试化合物治疗的心脏组织的心室复极化时间的测试化合物。 所述方法还包括确定特定剂量的测试化合物的心律失常风险评分。

Patent Agency Ranking